RNA vs XLF
Atrium Therapeutics, Inc. Common Stock (RNA) versus XLF (XLF) — a side-by-side from cached financials, not a winner call.
Atrium Therapeutics, Inc. Common Stock (RNA) is a biotechnology company listed on NASDAQ.
XLF (XLF) common stock.
Latest reported RNA revenue for 2026-06-30 was $22.6M. Net income was -$36.8M. Revenue was up 15.3% from 2026-03-31 to 2026-06-30. RNA currently screens at market cap $217.5M.
XLF does not have a complete income-statement cache yet.
RNA currently screens at market cap $217.5M. XLF currently screens at market cap $0.
Not investment advice. Open the RNA and XLF stock pages for the full models.
Not investment advice.